What is Knome?
Knome operates at the intersection of clinical diagnostics and pharmaceutical research, providing the essential bioinformatics infrastructure required to translate complex genomic data into actionable insights. Its flagship platform, knoSYS, serves as a scalable informatics backbone for next-generation sequencing (NGS) programs, allowing clinicians and researchers to interpret human genomic data with unprecedented precision.
Beyond its software offerings, the company provides the knomeDISCOVERY service, a specialized solution tailored for pharmaceutical and academic entities engaged in large-scale exome and genome studies. By streamlining the analysis of biological data, Knome empowers its partners to enhance the efficiency of drug discovery and clinical testing, effectively positioning itself as a foundational player in the precision medicine ecosystem.
How much funding has Knome raised?
Knome has raised a total of $23.8M across 3 funding rounds:
Private Equity
$5M
Debt
$5.8M
Private Equity
$13M
Private Equity (2010): $5M, investors not publicly disclosed
Debt (2012): $5.8M, investors not publicly disclosed
Private Equity (2014): $13M, investors not publicly disclosed
Key Investors in Knome
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Knome?
With the recent infusion of capital, Knome is poised to deepen its market penetration within the pharmaceutical sector and expand the capabilities of its informatics suite. The company's strategic roadmap likely involves enhancing the computational throughput of the knoSYS platform to accommodate the increasing volume of genomic data generated by global research initiatives.
As the industry shifts toward more personalized therapeutic approaches, Knome's focus on scalable, high-fidelity data interpretation will be critical. The firm is expected to leverage this latest financing to bolster its research partnerships, potentially expanding its footprint in clinical settings where rapid, accurate genomic analysis is a prerequisite for patient care and drug development success.
